Over the next six years, 10 drugs that are in the pre-registration phase and expected to launch during 2020 are projected to reach blockbuster status.
The U.S. Food and Drug Administration gave Italian firm Recordati and Novartis’ Isturisa (osilodrostat) marketing clearance for adults with Cushing’s disease who either can not have pituitary gland surgery or who have had the surgery but still have the disease.
The U.S. Food and Drug Administration approved Allergan’s Durysta (bimatoprost implant) 10 mcg for intracameral administration to treat open-angle glaucoma (OAG) or ocular hypertension.
The U.S. Food and Drug Administration gave the green light to Sanofi’s Sarclisa (isatuximab-irfc) in combination with pomalidomide and dexamethasone (pom-dex) for adults with multiple myeloma who have had two previous therapies including lenalidomide and a protease inhibitor.
The U.S. Food and Drug Administration approved Ann Arbor, Michigan-based Esperion’s Nexlizet (bempedoic acid and ezetimibe) for lowering LDL cholesterol.
Shares of Acacia Pharma skyrocketed in trading after the company announced FDA approval for Barhemsys (amisulpride injection) for the prevention and treatment of postoperative nausea and vomiting (PONV) in adults.
The U.S. Food and Drug Administration approved Michigan-based Esperion’s oral, once-daily, non-statin LDL-cholesterol lowering medicine Nexletol (bempedoic acid).
Seqirus snagged U.S. FDA approval for Fluad Quadrivalent, the first quadrivalent adjuvanted influenza vaccine developed to help protect adults 65 years and older against seasonal influenza.
Shares of Pennsylvania-based Baudax Bio were up more than 40 percent after the company announced that the pain medication Anjeso was greenlit by the U.S. Food and Drug Administration.
The U.S. Food and Drug Administration approved Eagle Pharmaceuticals’ Pemfexy (pemetrexed for injection) as a branded alternative to Eli Lilly and Co.’s Alimta.
